Neomycin

Introduction Overview

Generic Name

neomycin

Brand Name

Mycifradin, Neo-Fradin, Neo-Tab

Dosage Form

oral tablet (500 mg)

Drug Class

Aminoglycosides

Pharmacokinetics

Absorption:
Neomycin, when administered orally, exhibits minimal systemic absorption due to its hydrophilic nature and large molecular size, which limits its passage through the gastrointestinal mucosa. This property is beneficial when targeting infections within the intestines, as the drug remains predominantly in the gut lumen. However, even minimal absorption can lead to systemic exposure, especially in cases of compromised gastrointestinal integrity, which may increase risks of nephrotoxicity and ototoxicity. Absorption can be affected by the presence of food, gastrointestinal pH, and motility, though these factors tend to have limited clinical impact due to the drug's poor oral bioavailability.

Distribution:
After minimal absorption, neomycin distributes primarily in extracellular fluids without significant protein binding. Systemically absorbed neomycin preferentially accumulates in renal cortical tissue and the inner ear. The concentration in these tissues is clinically important, as it underpins the drug's known nephrotoxic and ototoxic side effects. Neomycin does not readily cross the blood-brain barrier nor does it significantly accumulate in fatty tissues due to its hydrophilicity.

Metabolism:
Neomycin is not metabolized extensively in the body. The majority of the administered oral dose passes through the gastrointestinal tract unchanged. Lack of significant metabolism reduces the complexity of drug interactions mediated by metabolic enzymes such as cytochrome P450 but requires consideration of renal elimination pathways.

Elimination:
Systemically absorbed neomycin is excreted primarily unchanged by glomerular filtration in the kidneys. The renal elimination half-life ranges from 2 to 3 hours in patients with normal kidney function but may be dramatically prolonged in cases of renal impairment, increasing the risk of accumulation and toxicity. Because oral administration yields minimal systemic absorption, fecal elimination predominantly accounts for drug clearance in this route, with most unchanged drug recovered in stool. Monitoring renal function is critical during therapy to prevent adverse effects associated with accumulation.

Dosage Forms

Available Dosage Forms:
Neomycin is commercially available as oral tablets, specifically a 500 mg oral tablet formulation. This dosage form is designed for gastrointestinal indications where local antibiotic activity in the intestines is desired. The oral formulation exploits neomycin’s poor systemic absorption to achieve high gut lumen concentrations with minimal systemic exposure.

Dosages for Adults and Adolescents:
For intestinal sterilization and prevention of bacterial infections in the intestines, the typical adult dosage of neomycin oral tablets is 4.5 to 6 grams per day, divided into three doses, not to exceed two weeks of therapy to mitigate risks of nephrotoxicity and ototoxicity. In hepatic coma management, the dosing usually involves administration for 5 to 6 days, with concurrent dietary protein restrictions to lessen ammonia production in the gut.

Specific Patient Populations:
Dosage adjustments are critical for patients with renal impairment due to increased risks of systemic toxicity from even minimal absorption. Children should not receive neomycin without medical advice because of vulnerability to adverse effects. Pregnant patients should use neomycin only if clearly needed due to potential teratogenic effects. Breastfeeding is contraindicated during treatment due to risk of drug transmission and toxicity in the infant. Special consideration for hepatic coma includes a restricted protein diet while on therapy, guided by a dietitian.

Mechanism Of Action

Neomycin’s primary mechanism of action is the inhibition of bacterial protein synthesis by binding irreversibly to the 30S ribosomal subunit. This binding induces misreading of mRNA and interrupts the initiation complex formation necessary for translation. Consequently, it produces bactericidal effects against susceptible gram-negative and some gram-positive bacteria.

At the molecular level, neomycin interacts specifically with the decoding site of the 16S rRNA within the 30S ribosomal subunit. This binding stabilizes an erroneous tRNA-mRNA pairing, promoting incorporation of incorrect amino acids into nascent peptides, thereby producing dysfunctional or toxic proteins leading to bacterial cell death.

Neomycin also affects bacterial membrane integrity at higher concentrations, increasing membrane permeability and potentiating its bactericidal activity. This additional biochemical action may contribute to its efficacy against enteric pathogens.

Clinically, the local administration of neomycin into the gastrointestinal tract leverages poor absorption to achieve high luminal antibiotic concentrations, effectively eradicating pathogenic bacteria responsible for intestinal infections and reducing nitrogenous waste formation in hepatic encephalopathy. Compared with other aminoglycosides like gentamicin, neomycin’s oral use is preferred for gut decontamination due to its limited systemic absorption and resultant reduced systemic toxicity.

Pharmacological Actions

Bactericidal antibiotic activity primarily against aerobic gram-negative bacteria and some gram-positive bacteria.
Inhibits bacterial protein synthesis by binding irreversibly to the 30S ribosomal subunit.
Disrupts bacterial membrane integrity at higher concentrations, increasing permeability.
Exerts local antibacterial effects in the intestinal lumen due to minimal systemic absorption.
Reduces bacterial flora responsible for nitrogenous waste production in hepatic coma.
Used as an intestinal antiseptic to sterilize bowels preoperatively or to control infections.
Demonstrates rapid onset of action due to high luminal concentrations upon oral administration.
Minimal metabolism with primary elimination unchanged via feces in oral administration.
Concomitant use may exhibit additive or synergistic effects with other antibiotics.
Potential nephrotoxic and ototoxic effects when absorbed systemically, requiring careful monitoring.

Therapeutic Or Clinical Uses

Prevention and treatment of bacterial infections localized within the intestines.
Reduction of intestinal bacterial flora in preparation for colorectal surgery (bowel sterilization).
Management of hepatic coma by reducing bacterial ammonia production and absorption.
Adjunctive therapy combined with other antibiotics for systemic infections when topical or oral use is applicable.
Treatment of infections caused by susceptible strains of Escherichia coli, Proteus species, and other enteric pathogens.
Used in bowel preparation regimens prior to surgery or diagnostic procedures involving the gastrointestinal tract.
Reduction of bacterial contamination in patients with impaired intestinal integrity.
Off-label use for decontamination in multi-drug resistant bacterial colonization in critical care.
Decreases risk of infection transmission via gut bacteria in immunocompromised patients.

Side Or Adverse Effects

Nephrotoxicity manifesting as swelling, decreased urine output, fatigue, and shortness of breath due to renal impairment.
Ototoxicity including tinnitus, hearing loss, vertigo, and balance disorders, potentially permanent.
Neurotoxicity presenting as muscle twitching, seizures, or paresthesias (numbness, tingling) under the skin.
Gastrointestinal upset including nausea, vomiting, and diarrhea.
Hypersensitivity reactions such as rash, hives, and potentially life-threatening anaphylaxis.
Allergic reactions involving swelling of the face, lips, tongue, or throat that may impair breathing.
Potential exacerbation of neuromuscular blockade, leading to respiratory depression or paralysis.
Rare occurrences of superinfection or overgrowth of non-susceptible organisms (e.g., fungi).
Black hairy tongue as an uncommon consequence of altered oral flora and epithelial changes.
Potential for auditory nerve damage especially with prolonged or excessive dosing.

Precautions

Avoid use in patients with known hypersensitivity to neomycin or other aminoglycosides.
Use cautiously in patients with pre-existing renal impairment or hearing loss.
Monitor kidney function and hearing parameters regularly during therapy.
Avoid prolonged courses and high cumulative doses to minimize toxicities.
Not recommended in patients with inflammatory bowel disease such as ulcerative colitis or Crohn's disease due to potential for worsening symptoms.
Avoid use in patients with intestinal obstructions or perforations.
Exercise caution in patients with neuromuscular disorders such as myasthenia gravis or Parkinson's disease.
Pregnant women should use neomycin only if benefits justify risks, as it may harm an unborn baby.
Breastfeeding is contraindicated during neomycin therapy to prevent neonatal exposure.
Do not use in pediatric patients unless explicitly prescribed by a healthcare provider.
Avoid concurrent use with other nephrotoxic or ototoxic drugs.
Maintain adequate hydration to support renal clearance during treatment.

Warnings

Risk of permanent hearing loss if neomycin is taken in excessive doses or for extended periods.
Possible irreversible nephrotoxicity necessitating regular renal function assessment.
Neurotoxicity risk including seizures, muscle twitching, and respiratory depression.
Contraindicated in patients allergic to neomycin or structurally related aminoglycosides.
Potential exacerbation of neuromuscular blockade especially in patients receiving anesthetics or muscle relaxants.
Avoid use in inflammatory bowel diseases and intestinal obstructions.
Use in hepatic coma requires dietary protein modification to prevent exacerbation of encephalopathy.
Not effective against viral infections; inappropriate use can contribute to antimicrobial resistance.
Emergency medical attention required for signs of allergic reactions including facial swelling and breathing difficulties.
Neomycin-containing products should never be shared between individuals to prevent cross-infection or inappropriate dosing.

Contraindication

Hypersensitivity to neomycin or other aminoglycoside antibiotics such as amikacin, gentamicin, kanamycin, paromomycin, streptomycin, or tobramycin.
Patients with ulcerative colitis or Crohn's disease due to risk of exacerbating intestinal inflammation.
Presence of intestinal obstruction or ileus where altered gut flora may worsen clinical status.
Known auditory or vestibular nerve damage stemming from prior aminoglycoside therapy.
Patients with myasthenia gravis or other neuromuscular disorders at risk of potentiated neuromuscular blockade.
Neonates and infants without explicit medical guidance due to immature renal and auditory systems.
Pregnancy unless clearly needed and benefits outweigh risks.
Breastfeeding due to potential transfer and toxicity in the infant.
Concurrent use with other ototoxic or nephrotoxic agents unless under strict medical supervision.

Drug Interactions

Additive nephrotoxicity when combined with other nephrotoxic agents such as amphotericin B, cisplatin, or vancomycin.
Increased ototoxicity risk when used concurrently with loop diuretics like furosemide or ethacrynic acid.
Potential enhanced neurotoxicity and neuromuscular blockade with concomitant use of anesthetics or muscle relaxants.
Reduced efficacy or toxicity concerns when combined with other antibiotics that may interfere antagonistically.
Interactions with digoxin may increase risk of digoxin toxicity due to altered renal clearance or electrolyte imbalances.
Concurrent use with methotrexate or fluorouracil may require monitoring due to overlapping toxicities.
Co-administration with blood thinners such as warfarin may necessitate closer coagulation monitoring.
Interactions with vitamin B-12 supplementation agents without significant clinical impact but require assessment.
Use with certain immunosuppressants post-organ transplant may increase susceptibility to nephrotoxicity.
Overlapping toxicities with other agents used in high blood pressure or arthritis treatments, including NSAIDs.
Potential interaction with herbal supplements that affect kidney function or hearing, necessitating careful review.

Preparations Of The Drug

Oral tablet formulation containing 500 mg of neomycin sulfate, intended for oral administration.
Formulated for poor gastrointestinal absorption to exert local antibacterial action in the intestines.
Available under brand names such as Mycifradin, Neo-Fradin, and Neo-Tab.
Packaged with instructions to avoid exceeding prescribed dose and duration to prevent toxicity.
Supplied with patient information emphasizing hydration and dietary modifications during hepatic coma treatment.
Stored at room temperature, protected from moisture and heat to maintain stability.
Dispensed with warnings regarding avoidance in inflammatory bowel disease and gastrointestinal obstruction.
Prepared for use in bowel sterilization, hepatic encephalopathy, and related intestinal infections.
Manufactured to pharmaceutical standards ensuring purity, potency, and consistency of active ingredient.
Often accompanied by educational materials detailing adverse effects, monitoring requirements, and precautions.